$IH

iHuman Inc.

No enriched coverage for $IH in the last 7 days.

No SEC Form 4 filings for $IH in the last 30 days.

Med

iHuman posts 2025 Form 20-F, offers free audited hard copies

iHuman Inc. (NYSE: IH) announced it filed its 2025 annual report on Form 20-F with the U.S. Securities and Exchange Commission on April 24, 2026, for the fiscal year ended December 31, 2025. The report, including audited financial statements, is available on the company's investor relations website. Shareholders and American Depositary Share (ADS) holders can also request a free hard copy by contacting iHuman's Beijing office.

iHuman Inc. Sponsored ADR (NYSE:IH) Short Interest Up 311.4% in March

iHuman Inc. Sponsored ADR (NYSE:IH) experienced a significant surge in short interest during March, increasing by 311.4% to 1,876 shares. This comes after a "Sell" rating from Weiss Ratings and an overall "Sell" consensus from analysts, despite a hedge fund, Acadian Asset Management LLC, recently acquiring a new position in the company. The stock exhibited a daily trading volume of 5,346 shares and closed at $1.79 on Wednesday, suggesting a relatively low days-to-cover ratio.

iHuman (NYSE: IH) director lists 144M Class B share stake

iHuman Inc. director Chi Yufeng has filed an initial statement of beneficial ownership (Form 3) revealing indirect holdings of 144,000,000 Class B ordinary shares through Academy Management Ltd. This filing is a disclosure of an existing substantial stake rather than a new transaction, indicating no recent purchase or sale by the director. The report specifies the nature of the security as Class B ordinary shares.